Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Pedigree Analysis01:35

Pedigree Analysis

Overview
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States.

Blood advances·2026
Same author

Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.

The Lancet. Haematology·2026
Same author

Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study.

Blood vessels, thrombosis & hemostasis·2026
Same author

[Clinical efficacy of anterior cervical mortise-tenon corpectomy and fusion for the treatment of ossification of the posterior longitudinal ligament].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2026
Same author

Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses.

Seminars in thrombosis and hemostasis·2026
Same author

Bone Mineral Density, Bone Remodeling Biomarkers, and Hemostatic Correlates in Hemophilia and von Willebrand Disease.

Blood advances·2026

Related Experiment Video

Updated: May 20, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.

Divyaswathi Citla-Sridhar1, Jianzhong Hu2, Robert F Sidonio3

  • 1Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, AR.

Journal of Pediatric Hematology/Oncology
|May 19, 2026
PubMed
Summary

This study reveals significant bleeding and treatment patterns in inherited platelet function disorders (IPFDs), highlighting the need for improved diagnostic precision and patient care.

Keywords:
Bernard-Soulier syndromeGlanzmann thrombastheniableeding disordersplatelet disorders

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Related Experiment Videos

Last Updated: May 20, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Inherited platelet function disorders (IPFDs) are rare and diverse, presenting diagnostic and management difficulties.
  • Glanzmann thrombasthenia (GT) and Bernard-Soulier syndrome (BSS) bleeding is known, but milder or unclassified IPFDs are poorly understood.

Purpose of the Study:

  • To analyze bleeding phenotypes, treatment strategies, and diagnostic distribution of IPFDs in the U.S. using the ATHNdataset.
  • To characterize clinical outcomes for patients with IPFDs from 2013-2022.

Main Methods:

  • Retrospective cohort study utilizing the deidentified ATHNdataset.
  • Analysis of clinical outcomes, bleeding events, laboratory data, treatments, and procedures for IPFD patients with active follow-up (2021-2022).

Main Results:

  • Over 2300 individuals had IPFDs, with 81.6% classified as IPFD-other.
  • Epistaxis, soft tissue, and oral bleeding were most common; intracranial hemorrhage and joint bleeds occurred in 8 and 82 patients, respectively.
  • Elevated ISTH-BAT scores noted across subtypes, with antifibrinolytics being the most common treatment.

Conclusions:

  • The study defines the clinical spectrum, treatment use, and diagnostic gaps in IPFDs.
  • Emphasizes the critical need for enhanced diagnostic accuracy and improved care for patients with platelet function disorders.